Alterity's update previews regulatory feedback and proposed development plans for a novel therapy addressing multiple system atrophy.
Key Takeaways
- FDA agreed a single pivotal Phase 3 trial could support an NDA filing
- FDA aligned on a primary endpoint using the 11-item UMSARS Part I
- ATH434 showed randomized Phase 2 efficacy, biomarker engagement, and favorable safety